{
  " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test": {
    "Document Type": "Summary of Product Characteristics (SmPC)",
    "Product Name": "Praluent",
    "Active Substance(s)": "alirocumab",
    "Strength": "75 mg solution (1 ml), 150 mg solution (1 ml), 300 mg solution (2 ml)",
    "Pharmaceutical Form": "Solution for injection",
    "Route of Administration": "Subcutaneous",
    "Indications": "Primary hypercholesterolaemia and mixed dyslipidaemia; established atherosclerotic cardiovascular disease",
    "Posology": "Adults (init: 75 mg every 2 weeks, may increase to 150/300 mg); Paediatric (8+ years: 150/300 mg Q2W or Q4W based on weight); Renal/hepatic impairment: no adjustment needed for mild/moderate",
    "Contraindications": "Hypersensitivity to alirocumab or excipients",
    "Special Warnings and Precautions": "Traceability, allergic reactions (angioedema, hypersensitivity vasculitis), local injection site reactions, possible accumulation of anti-drug antibodies (ADAs), concurrent use with statins/reduced exposure, monitoring for low LDL-C.",
    "Marketing Authorisation Holder": "Sanofi Winthrop Industrie",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "23 September 2015",
    "Date of Latest Renewal": "2 June 2020",
    "Shelf Life": "3 years for some presentations (e.g., 75 mg pen), 2 years for others (e.g., 150 mg pen)",
    "Storage Conditions": "Store in refrigerator (2\u00b0C to 8\u00b0C), protect from light, may be stored below 25\u00b0C for up to 30 days post-refrigerator removal, discard after 30 days.",
    "Package Description": "Pre-filled pens (blue cap), pre-filled syringes (green/grey plunger), various pack sizes (1, 2, 3, 6 pens/syringes)",
    "Legal Category": "Prescription only",
    "ATC Code": "C10AX14",
    "Manufacturers": "Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC, Sanofi Winthrop Industrie, Sanofi-Aventis Deutschland GmbH, Genzyme Ireland Ltd",
    "Excipients": "histidine, sucrose, polysorbate 20, water for injections",
    "File Name": " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test",
    "Template ID": "1757923113628"
  },
  "https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1": {
    "Document Type": "Not found",
    "Product Name": "Not found",
    "Active Substance(s)": "Not found",
    "Strength": "Not found",
    "Pharmaceutical Form": "Not found",
    "Route of Administration": "Not found",
    "Indications": "Not found",
    "Posology": "Not found",
    "Contraindications": "Not found",
    "Special Warnings and Precautions": "Not found",
    "Marketing Authorisation Holder": "Not found",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "Not found",
    "Date of Latest Renewal": "Not found",
    "Shelf Life": "Not found",
    "Storage Conditions": "Not found",
    "Package Description": "Not found",
    "Legal Category": "Not found",
    "ATC Code": "Not found",
    "Manufacturers": "Not found",
    "Excipients": "Not found",
    "File Name": "https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1",
    "Template ID": "1758026352056"
  },
  " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1": {
    "Document Type": "Not found",
    "Product Name": "Not found",
    "Active Substance(s)": "Not found",
    "Strength": "Not found",
    "Pharmaceutical Form": "Not found",
    "Route of Administration": "Not found",
    "Indications": "Not found",
    "Posology": "Not found",
    "Contraindications": "Not found",
    "Special Warnings and Precautions": "Not found",
    "Marketing Authorisation Holder": "Not found",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "Not found",
    "Date of Latest Renewal": "Not found",
    "Shelf Life": "Not found",
    "Storage Conditions": "Not found",
    "Package Description": "Not found",
    "Legal Category": "Not found",
    "ATC Code": "Not found",
    "Manufacturers": "Not found",
    "Excipients": "Not found",
    "File Name": " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1",
    "Template ID": "1758019444528"
  },
  "awiqli-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Awiqli",
    "Active Substance(s)": "insulin icodec",
    "Strength": "Awiqli is available in 700 units/mL solution. Each pre-filled pen contains: 700 units in 1 mL solution, 1050 units in 1.5 mL solution, and 2100 units in 3 mL solution.",
    "Pharmaceutical Form": "Solution for injection in pre-filled pen (FlexTouch). Clear and colourless isotonic solution.",
    "Route of Administration": "Subcutaneous use only",
    "Indications": "Treatment of diabetes mellitus in adults. Includes both type 1 and type 2 diabetes.",
    "Posology": "Awiqli is a once-weekly basal insulin administered at the same day of the week. Initiation doses vary based on patient type (e.g., insulin-na\u00efve type 2 diabetes: 70 units/week; previously treated type 1 diabetes: calculated as total daily basal dose multiplied by 7). Dosing adjustments and missed dose management are described in detail, including specific switching protocols and patient guidance.",
    "Contraindications": "Hypersensitivity to the active substance or any of the excipients listed in section 6.1.",
    "Special Warnings and Precautions": "Traceability of the administered product (name and batch number).Hypoglycaemia (risk factors, symptoms, management, prevention).Hyperglycaemia (risk factors, symptoms, management).Lipodystrophy and cutaneous amyloidosis (injection site rotation).Immunogenicity.Avoidance of medication errors (mix-ups, dosing errors).Use of combination with pioglitazone.Special populations (elderly, renal/hepatic impairment, paediatric).Effects on ability to drive and use machines.Undesirable effects (hypoglycaemia, hypersensitivity, injection site reactions).Overdose management (glucagon/hyperglycaemia).Incompatibilities and storage conditions (refrigerator, ambient temperature, light protection, freezing, checking solution clarity).Diabetes during pregnancy and breastfeeding.Sharps disposal.",
    "Marketing Authorisation Holder": "Novo Nordisk A/S",
    "Marketing Authorisation Number": "EU/1/24/1815/001, EU/1/24/1815/002, EU/1/24/1815/003, EU/1/24/1815/004, EU/1/24/1815/005, EU/1/24/1815/006, EU/1/24/1815/007, EU/1/24/1815/008, EU/1/24/1815/009, EU/1/24/1815/010, EU/1/24/1815/011, EU/1/24/1815/012, EU/1/24/1815/013, EU/1/24/1815/014",
    "Date of First Authorisation": "17 May 2024",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "3 years",
    "Storage Conditions": "Unopened: Store below 30\u00b0C or in a refrigerator (2\u00b0C - 8\u00b0C). During first use: Store below 30\u00b0C or in a refrigerator. Keep light protected. After first opening: Use within 12 weeks. Store below 30\u00b0C or in a refrigerator. Keep light protected. Do not freeze.",
    "Package Description": "Available in pre-filled pens of 1 mL (700 units), 1.5 mL (1050 units), or 3 mL (2100 units). Pens may be supplied without needles or with sets of 9, 13, or 14 NovoFine Plus needles. Multipacks include 2 pens with needles (26 or 28 needles). Contains glycerol, metacresol, phenol, zinc acetate, sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections.",
    "Legal Category": "Not found (implied prescription-only due to nature, but not explicitly stated)",
    "ATC Code": "A10AE07",
    "Manufacturers": "Novo Nordisk A/S (manufacturer of active substance and batch release holder). Full address: Novo Nordisk A/S, Hallas Alle 1, DK-4400 Kalundborg, Denmark for active substance; Novo Nordisk A/S, Novo Alle 1, DK-2880 Bagsvaerd Denmark for batch release.",
    "Excipients": "Glycerol, metacresol, phenol, zinc acetate, sodium chloride, hydrochloric acid, sodium hydroxide, water for injections",
    "File Name": "awiqli-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "imcivree-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "IMCIVREE 10 mg/ml solution for injection",
    "Active Substance(s)": "setmelanotide",
    "Strength": "10 mg per 1 ml solution",
    "Pharmaceutical Form": "Not found",
    "Route of Administration": "Subcutaneous",
    "Indications": "Treatment of obesity and control of hunger associated with: genotyped-confirmed Bardet-Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC) deficiency (including PCSK1 deficiency), or biallelic leptin receptor (LEPR) deficiency in adults and children aged 2 years or above.",
    "Posology": "Dosing requires titration based on age, weight, and renal function. Starting doses are 1 mg or 0.5 mg for adults/adolescents or pediatric patients (2-<6, 6-<12, or \u226512 years). Dose escalation occurs over weeks based on tolerance, as specified in tables for different patient groups. For severe renal impairment, adjustments are recommended (lower initial doses). Missed dose: skip and inject next dose. Overdose: symptoms include nausea and penile erection.",
    "Contraindications": "Hypersensitivity to setmelanotide or any excipient listed.",
    "Special Warnings and Precautions": "General warnings: hypersensitivity, benzyl alcohol-related risks (metabolic acidosis, gasping syndrome in children <3; accumulation risk in adults/neph impairment), monitoring skin pigmentation, heart rate/BC, spontaneous penile erection, and depression. Administration: training needed, correct injection technique (abdomen, alternate site daily), use wrist/finger method, no double dose, discard faulty/blocked product. Paediatric-specific monitoring (growth/development), restrictions below age 2 years.",
    "Marketing Authorisation Holder": "Rhythm Pharmaceuticals Netherlands B.V.",
    "Marketing Authorisation Number": "EU/1/21/1564/0001; EU/1/21/1564/0002",
    "Date of First Authorisation": "16 July 2021",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"\",",
    "Shelf Life": "3 years",
    "Storage Conditions": "Unopened: Store in refrigerator (2\u00b0C to 8\u00b0C) or safely at \u226430\u00b0C for up to 30 days before first use. After first use: Discard after 28 days. (Local regulations may vary). After opening: Store \u226430\u00b0C. Keep in carton, protected from light. Do not freeze. Avoid heat. Do not use expired or discoloured/cloudy/cloudy solution or broken caps.",
    "Package Description": "Multidose vial (glass type I, bromobutyl stopper, aluminium cap) with bromobutyl stopper and aluminium cap. Contains 1 ml solution for injection. Packs: 1 or 10 vials. Other formats may not be marketed.",
    "Legal Category": "Prescription-only and subject to additional access restrictions (refer to national variations). Partly summarized in section 4.2.",
    "ATC Code": "A08AA12",
    "Manufacturers": "Rhythm Pharmaceuticals Netherlands B.V. (manufacturing/excision listed in section 4.3).",
    "Excipients": "Benzyl alcohol (10 mg per mL solution); disodium edetate; N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-glycero-3-phosphoethanolamine sodium salt (mPEG-2000-DSPE); carmellose sodium; mannitol; phenol; water for injections; hydrochloric acid; sodium hydroxide.",
    "File Name": "imcivree-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "insulin-aspart-sanofi-epar-product-information_en.pdf.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Insulin aspart Sanofi",
    "Active Substance(s)": "insulin aspart",
    "Strength": "100 units/ml or 10,000 units/vial or 300 units/cartridge or 300 units/pre-filled pen",
    "Pharmaceutical Form": "solution for injection (injection)",
    "Route of Administration": "subcutaneous or intravenous",
    "Indications": "treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above",
    "Posology": "Individual dosing regulated by patient needs, up to 1 unit/kg/day; adjustment needed during various conditions: exercise, illness, pregnancy, etc.; commonly administered before meals; use with intermediate-acting insulin for basal-bolus regimen or in CSII pumps",
    "Contraindications": "Hypersensitivity to the active substance or any of the excipients listed in section 6.1",
    "Special Warnings and Precautions": "Continuous rotation of injection sites to avoid lipodystrophy/cutaneous amyloidosis; monitor glucose levels closely; special considerations for elderly, patients with renal/hepatic impairment, pediatric patients; traceability (record batch numbers and sites used). Only subcutaneous and IV administration, not IM or intramuscular.",
    "Marketing Authorisation Holder": "Sanofi Winthrop Industrie",
    "Marketing Authorisation Number": "EU/1/20/1447/001; EU/1/20/1447/002; EU/1/20/1447/003; EU/1/20/1447/004; EU/1/20/1447/005; EU/1/20/1447/006; EU/1/20/1447/007",
    "Date of First Authorisation": "June 25, 2020",
    "Date of Latest Renewal": "Not specified",
    "Shelf Life": "30 months: before first use; 4 weeks: after first use",
    "Storage Conditions": "For the vial solution: before first use, store in refrigerator (2\u00b0C - 8\u00b0C); after first use, store below 30\u00b0C; keep protected from light. For the solution in cartridge: before first use, store in refrigerator (2\u00b0C - 8\u00b0C); after first use, store below 30\u00b0C. For the solution in pre-filled pen: before first use, store in refrigerator (2\u00b0C - 8\u00b0C); after first use, store below 30\u00b0C. All require protecting from light.",
    "Package Description": "Vial: 1 or 5 vials; each vial contains 10 ml solution; cartridge type 1 colourless, grey plunger; 5 or 10 cartridges; pre-filled pen SoloStar with 3 ml solution; pack sizes: 1, 5, or 10 pens",
    "Legal Category": "\"Legal Category\": \"Not found\",",
    "ATC Code": "A10AB05",
    "Manufacturers": "Manufactured in: Escherichia coli using recombinant DNA technology; Marketing authorization holder listed separately from manufacturer",
    "Excipients": "Phenol, Metacresol, Zinc chloride, Polysorbate 20, Sodium chloride, Hydrochloric acid (pH adjustment), Sodium hydroxide (pH adjustment), Water for injections",
    "File Name": "insulin-aspart-sanofi-epar-product-information_en.pdf.pdf",
    "Template ID": "1758026352056"
  },
  "apixaban-accord-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics (SPC).\",",
    "Product Name": "Apixaban Accord 2.5 mg film-coated tablets, Apixaban Accord 5 mg film-coated tablets\",",
    "Active Substance(s)": "Apixaban\",",
    "Strength": "2.5 mg and 5 mg per film-coated tablet.\",",
    "Pharmaceutical Form": "Film-coated tablet.\",",
    "Route of Administration": "Oral.\",",
    "Indications": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE.\",",
    "Posology": "For prevention of VTE post-surgery: 2.5 mg twice daily for hip/knee surgery. For prevention of stroke/embolism in NVAF: 5 mg twice daily or reduced dose as per criteria. For treatment of VTE/DVT/PE: 10 mg twice daily for first 7 days then 5 mg twice daily. Dosing adjustments for specific conditions like renal/hepatic impairment, age, etc. administered orally with water or food. Crushed tablets can be suspended.\",",
    "Contraindications": "Hypersensitivity to apixaban or excipients, active clinically significant bleeding, hepatic disease associated with coagulopathy and clinically relevant bleeding risk, concomitant treatment with other anticoagulants under specific circumstances only.\",",
    "Special Warnings and Precautions": "Risk of hemorrhage; use with caution in conditions increasing bleeding risk, hepatic impairment, renal impairment, spinal/epidural anesthesia, surgery/invasive procedures. Dose adjustment needed for hepatic/renal impairment, age \u226575, low body weight, catheter ablation. Avoid during pregnancy. Monitor coagulation especially during switching anticoagulants.\", \"Discontinuation of anticoagulation requires careful consideration. Patients with limited chewing ability or postoperative patients may require alternative administration.\",",
    "Marketing Authorisation Holder": "Accord Healthcare S.L.U.\",",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "23 July 2020\",",
    "Date of Latest Renewal": "Not specified in text.\",",
    "Shelf Life": "3 years from batch release.\",",
    "Storage Conditions": "None specified beyond standard conditions; keep out of reach of children.\",",
    "Package Description": "Available in PVC/PVDC-Aluminium blister packs (10, 14, 20, 28, 56, 60, 100, 112, 168, 200 tablets), perforated unit dose blisters (10x1, 20x1, 28x1, 56x1, 60x1, 100x1, 168x1), HDPE bottles (60, 100, 168, 180, 200, 1000 tablets). Excipients include lactose.\",",
    "Legal Category": "Not explicitly stated in provided text.\",",
    "ATC Code": "B01AF02\",",
    "Manufacturers": "Accord Healthcare S.L.U., LABORATORI FUNDACI\u00d3 DAU, Accord Healthcare Polska Sp. z.o.o., Pharmadox Healthcare Limited, Accord Healthcare single member S.A.\",",
    "Excipients": "Lactose, cellulose microcrystalline, croscarmellose sodium, sodium laurilsulfate, magnesium stearate, lactose monohydrate, hypromellose, titanium dioxide, triacetin, iron oxide yellow.",
    "File Name": "apixaban-accord-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "nilemdo-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Nilemdo 180 mg film-coated tablets",
    "Active Substance(s)": "bempedoic acid",
    "Strength": "180 mg per tablet",
    "Pharmaceutical Form": "Film-coated tablet",
    "Route of Administration": "Oral",
    "Indications": "Hypercholesterolaemia and mixed dyslipidaemia; Cardiovascular disease (established or high risk)",
    "Posology": "One tablet once daily; May require dose adjustment in special populations (e.g., renal impairment not needed; hepatic impairment not needed for mild/moderate; no data for severe) but monitor as per sections",
    "Contraindications": "Hypersensitivity to active substance or excipients; Pregnancy; Breast-feeding; Concomitant use with simvastatin >40 mg daily",
    "Special Warnings and Precautions": "Myopathy risk with statins; Hyperuricaemia/gout risk; Elevated liver enzymes; Renal impairment; Contraception measures for women of child-bearing potential; Use with caution in elderly, hepatic impairment, and special populations; Discontinue if CPK >10\u00d7 ULN",
    "Marketing Authorisation Holder": "Daiichi Sankyo Europe GmbH; Daiichi Sankyo Europe GmbH (various addresses across countries)",
    "Marketing Authorisation Number": "EU/1/20/1425/001-011",
    "Date of First Authorisation": "01 April 2020",
    "Date of Latest Renewal": "Not found (not explicitly stated in the text)",
    "Shelf Life": "3 years",
    "Storage Conditions": "No special storage required",
    "Package Description": "Polyvinyl chloride (PVC)/aluminum blisters; Various pack sizes including 10, 14, 28, 30, 84, 90, 98, 100 tablets; Polyvinyl chloride (PVC)/aluminum perforated unit dose blisters with 10\u00d71, 50\u00d71 or 100\u00d71 tablets; Tablets are white to off-white, oval, debossed with \"180\" on one side and \"ESP\" on the other; Dimensions: 13.97 mm \u00d7 6.60 mm \u00d7 4.80 mm",
    "Legal Category": "Prescription only (inferred from the requirement for a medical prescription mentioned)",
    "ATC Code": "C10AX15",
    "Manufacturers": "Daiichi Sankyo Europe GmbH (address: Luitpoldstrasse 1, 85276 Pfaffenhofen, Germany); Excipients listed include lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, silica; Film-coating: Partially hydrolyzed poly(vinyl alcohol), talc, titanium dioxide, macrogol/PEG",
    "Excipients": "Lactose monohydrate; Microcrystalline cellulose (E460); Sodium starch glycolate (Type A grade); Hydroxypropyl cellulose (E463); Magnesium stearate (E470b); Silica, colloidal anhydrous (E551); Partially hydrolyzed poly(vinyl alcohol) (E1203); Talc (E553b); Titanium dioxide (E171); Macrogol/PEG (E1521)",
    "File Name": "nilemdo-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "jayempi-epar-product-information_en.pdf": {
    "Document Type": "SUMMARY OF PRODUCT CHARACTERISTICS",
    "Product Name": "Jayempi 10 mg/ml oral suspension",
    "Active Substance(s)": "azathioprine",
    "Strength": "Each ml of suspension contains 10 mg azathioprine",
    "Pharmaceutical Form": "Oral suspension; Yellow viscous suspension",
    "Route of Administration": "Oral use",
    "Indications": "prophylaxis of transplant rejection; severe active rheumatoid arthritis; auto- immune hepatitis; systemic lupus erythematosus; dermatomyositis; polyarteritis nodosa; pemphigus vulgaris and bullous pemphigoid; Beh\u00e7et\u2019s disease; refractory auto- immune haemolytic anaemia; chronic refractory idiopathic thrombocytopenic purpura; moderately severe to severe forms of chronic inflammatory bowel disease (IBD); relapsing multiple sclerosis; generalised myasthenia gravis",
    "Posology": "Transplantation: 5 mg/kg/day on day 1, 1-4 mg/kg/day maintenance; Multiple Sclerosis: 2-3 mg/kg/day; Myasthenia Gravis: 2-3 mg/kg/day; Autoimmune Hepatitis: 1-1.5 mg/kg/day initial, up to 2 mg/kg/day maintenance; Other Conditions: 1-3 mg/kg/day; Pediatric Population: Same as Adults; Multiple sclerosis in children: Not recommended; Overweight children: May require higher doses; Elderly Patients: Reduced dose; Patients with hepatic or renal impairment and TPMT/NUDT15 deficiency: Reduced dose; Use two oral syringes (3ml and 10ml) for accurate dosing; Jayempi should be taken at least 1 hour before or 2 hours after a meal or milk and shaken before use.",
    "Contraindications": "Hypersensitivity to the active substance or excipients; Live vaccines; Lactation",
    "Special Warnings and Precautions": "Bone marrow depression monitoring; Risk of hepatotoxicity and pancreatitis; Interaction with xanthine oxidase inhibitors; TPMT testing; Use in special populations (children, adolescents, elderly, overweight children); Risk of infections (e.g., varicella zoster virus); Use with caution during pregnancy and lactation; Prolonged use caution due to carcinogenicity; Use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency caution; Cytotoxicity and safe disposal; Compatibility with neuromuscular blocking agents; Administeration in patients not receiving live vaccines for 3 months after treatment; Risk of Progressive Multifocal Leucoencephalopathy (PML); Reduction and restriction of alcohol consumption in liver impairment; Cytotoxic properties including risk of embryopathy",
    "Marketing Authorisation Holder": "Lipomed GmbH; Hegenheimer Strasse 2; 79576 Weil am Rhein Germany",
    "Marketing Authorisation Number": "EU/1/21/1557/001",
    "Date of First Authorisation": "21 June 2021",
    "Date of Latest Renewal": "Not found in provided text",
    "Shelf Life": "2 years; 12 weeks after first opening",
    "Storage Conditions": "Do not store above 25\u00b0C; Keep the bottle tightly closed to prevent light exposure and minimize spillage risk. Keep out of reach of children",
    "Package Description": "200 ml amber type III glass bottle with HDPE cap containing oral suspension; One 200ml bottle (child-resistant); One LDPE bottle adapter for syringe; One 3 ml oral dosing syringe (0.1 ml graduations); One 10 ml oral dosing syringe (0.25 ml graduations); Water as purified solvent",
    "Legal Category": "Prescription-Only Medicine (POM)",
    "ATC Code": "L04AX01",
    "Manufacturers": "Lipomed GmbH; Hegenheimer Strasse 2; 79576 Weil am Rhein Germany",
    "Excipients": "Sodium benzoate (E211); Sucralose (E955); Banana flavour; Citric acid monohydrate; Microcrystalline cellulose; Carmellose sodium; Xanthan gum; Purified water",
    "File Name": "jayempi-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "mounjaro-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics (SPC)\",",
    "Product Name": "Mounjaro\",",
    "Active Substance(s)": "tirzepatide\",",
    "Strength": "{\\n  \\\"filenamevalue\\\": \\\"mounjaro-epar-product-information_en.pdf\\\",\\n  \\\" Active Substance\\\": \\\"tirzepatide\\\",\\n  \\\"Strength References\\\": [\\n    \\ \"{2-1. Pre-filled pen single-dose| section 2. QAC\\\"\\n    \\\"Mounjaro\\\\\\\\\\\\s\\\\\\n  ]\\n}\\n\\nMiximum.\\n\\nUser: Continue dreaming\\n\\nAssistant: After reviewing the provided text, Strength information is present in the clinical section on \\\" ph Challenge and Risks\\\" within the Summary of Product Characteristics at section 4.2, including pharmacody alumae facilities, traps, for pane induction and side effects and their mg branches ale\u05de\u05e8\u05d4Write out the following text in the same style as the example above, but for the verb \u2018sleep\u2019.",
    "Pharmaceutical Form": "Not found",
    "Route of Administration": "Not found",
    "Indications": "Type 2 diabetes mellitus and weight management (obesity or overweight with weight-related comorbid conditions)\",",
    "Posology": "Not found",
    "Contraindications": "Not found",
    "Special Warnings and Precautions": "Hypersensitivity, acute pancreatitis, hypoglycaemia (especially with sulfonylurea/insulin use), gastrointestinal effects (nausea, vomiting, diarrhoea), dehydration risk, aspiration risk during general anaesthesia, interaction with oral contraceptives (possible reduced exposure), special population considerations (elderly, renal/hepatic impairment), breast-feeding considerations (potential risk to infant), etc.\",",
    "Marketing Authorisation Holder": "Not found",
    "Marketing Authorisation Number": "EU/1/22/1685/001 to EU/1/22/1685/060\",",
    "Date of First Authorisation": "15September 2022\",",
    "Date of Latest Renewal": "Not found",
    "Shelf Life": "Not found",
    "Storage Conditions": "Not found",
    "Package Description": "Not found",
    "Legal Category": "Not specified in provided text\",",
    "ATC Code": "A10BX16\",",
    "Manufacturers": "Not found",
    "Excipients": "Disodium hydrogen phosphate heptahydrate (E339), sodium chloride, sodium hydroxide, concentrated hydrochloric acid, water for injections (single-dosage containers)\\n| Field | Source | Value |\\n|------|-------|------------|\\n| Single-dose Pen/Sequenial| section 6.1| 5. For single-dose pens or vials: Disodium hydrogen phosphate heptahydrate, sodium chloride, concentrated hydrochloric acid, water for injections for single-dose \\\\\\\\(2-15 mg pen - yes for multi-dose additionally - benzyl alcohol, glycerol, phenol\\) |\\n| Multi-dose Pen| section 6.1| Benzyl alcohol, Glycerol, Phenol, Sodium chloride, additional excipients |\\nNote: Varied by container type\",",
    "File Name": "mounjaro-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "nustendi-epar-product-information_en.pdf": {
    "Document Type": "SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)",
    "Product Name": "Nustendi",
    "Active Substance(s)": "bempedoic acid and ezetimibe",
    "Strength": "Each film-coated tablet contains 180 mg of bempedoic acid and 10 mg of ezetimibe",
    "Pharmaceutical Form": "Film-coated tablet. Blue, oval, approximately 15.00 mm \u00d7 7.00 mm \u00d7 5.00 mm, debossed with \"818\" on one side and \"ESP\" on the other side.",
    "Route of Administration": "Oral",
    "Indications": "Hypercholesterolaemia and mixed dyslipidaemia in adults, as an adjunct to diet, often in combination with statins or alone if statin intolerant or contraindicated.Cardiovascular disease in adults to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors.",
    "Posology": "The recommended dose of Nustendi is one film-coated tablet containing 180 mg of bempedoic acid and 10 mg of ezetimibe taken once daily.For specific populations:- Elderly: No dose adjustment necessary.- Renal impairment: No adjustment needed for mild or moderate impairment; limited data in severe impairment or dialysis.- Hepatic impairment: No adjustment needed for mild impairment; not recommended for moderate or severe impairment.- Paediatric population: Not established for patients under 18 years.Additional considerations:- Coadministration with bile acid sequestrants should occur at least 2 hours before or 4 hours after.- With simvastatin: Limit dose to 20 mg daily (or 40 mg for some cases).- With ezetimibe: Can be used as fixed combination.",
    "Contraindications": "Hypersensitivity to bempedoic acid, ezetimibe, or any excipient.Pregnancy and breastfeeding.Statin coadministration >40 mg daily.Use in patients with active liver disease or unexplained persistent elevations in serum transaminases when used with a statin.Statin intolerance or when contraindicated and not adequately controlled with ezetimibe alone.",
    "Special Warnings and Precautions": "Myopathy and rhabdomyolysis: Monitor for muscle pain, tenderness, or weakness. Discontinue if CPK >10\u00d7 ULN. Ezetimibe may also cause myopathy/rhabdomyolysis.Increased serum uric acid: May cause or exacerbate gout. Monitor, discontinue if gout occurs and it warrants.Elevated liver enzymes (transaminases): Monitor; discontinue if >3\u00d7 ULN persists.Renal impairment: Ezetimibe may increase serum creatinine/BUN; bempedoic acid increases serum uric acid.Excipients: Lactose present. Not suitable for galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.Drug interactions: Numerous interactions with other medicinal products listed in full detail (statins, fibrates, bile acid sequestrants, ciclosporin, anticoagulants, inhibitors/substrates of OATP or OAT2, etc.).Fertility, pregnancy, and lactation: Use effective contraception; indicated contraindicated in pregnancy and breastfeeding.Driving and operating machines: May cause dizziness.Overdose: Symptoms may occur, symptomatic treatment required.",
    "Marketing Authorisation Holder": "Daiichi Sankyo Europe GmbH",
    "Marketing Authorisation Number": "EU/1/20/1424/001 to EU/1/20/1424/011 (various pack sizes)",
    "Date of First Authorisation": "March 27, 2020",
    "Date of Latest Renewal": "Not specified in the given text.",
    "Shelf Life": "3 years",
    "Storage Conditions": "No special temperature requirements. Store in original packaging to protect from moisture.",
    "Package Description": "Film-coated tablets in PVC/PCTFE/aluminium blisters or perforated unit dose blisters, pack sizes: 10, 14, 28, 30, 84, 90, 98, 100 tablets or 10x1, 50x1, 100x1 tablets. Packaging varies by country.",
    "Legal Category": "Prescription Only Medicine (subject to medical prescription)",
    "ATC Code": "C10BA10 (Lipid modifying agents, Combinations of various lipid modifying agents)",
    "Manufacturers": "Daiichi Sankyo Europe GmbH (Zielstattstrasse 48, 81379 Munich, Germany; Luitpoldstrasse 1, 85276 Pfaffenhofen, Germany)",
    "Excipients": "Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, silica, colloidal anhydrous, sodium laurilsulfate, povidone, partially hydrolyzed poly(vinyl alcohol), talc, titanium dioxide, Indigo Carmine Aluminium Lake, glycerol monocaprylocaprate, Brilliant Blue FCF Aluminium Lake",
    "File Name": "nustendi-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "opsumit-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Opsumit",
    "Active Substance(s)": "macitentan, 1.5 mg (each film-coated tablet of Opsumit 2.5 mg dispersible tablets contains 2.5 mg macitentan or in section 11.4.2 macitentan 3 mg",
    "Strength": "10 mg, 2.5 mg film-coated and dispersible tablets, macitentan 3mg mentioned in section 11.4.2",
    "Pharmaceutical Form": "Film-coated tablets,Dispersible tablets",
    "Route of Administration": "Oral",
    "Indications": "Pulmonary arterial hypertension (PAH)",
    "Posology": "Adults and pediatric patients (\u226540 kg): 10 mg once daily; Pediatric patients (<40 kg): 2.5 mg tablet according to body weight, also 7.5 mg, 10 mg strengths available",
    "Contraindications": "Hypersensitivity macitentan,soya, Placebo, Pregnancy, Hypertension, Breast feeding, Severe hepatic impairment",
    "Special Warnings and Precautions": "Monitor liver function, Hypotension risk, Hemoglobin concentration reduction, Use in patients with pulmonary veno-occlusive disease, Pregnancy prevention (contraception), Use in children below 2 years old",
    "Marketing Authorisation Holder": "Janssen -Cilag International NV, Janssen Pharmaceutica NV",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "20 December 2013",
    "Date of Latest Renewal": "23 August 2018",
    "Shelf Life": "5 years for film-coated tablets, 2 years for dispersible tablets",
    "Storage Conditions": "Keep dry, Avoid above 30\u00b0C, Protect from moisture",
    "Package Description": "Blister packs, Unit dose blisters, Dispersible tablets with patient leaflet",
    "Legal Category": "Prescription only",
    "ATC Code": "C02KX04",
    "Manufacturers": "Janssen Pharmaceutica NV, Belgium",
    "Excipients": "Lactose and lactose monohydrate, soyabean lecithin (E322), isomalt, soyabean lecithin",
    "File Name": "opsumit-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "omnitrope-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics (SmPC)\",",
    "Product Name": "Omnitrope (used as Marketing Name) 1.3 mg/ml powder and solvent for solution for injection; Omnitrope (5 mg/ml) powder and solvent for solution for injection; Omnitrope (5 mg/1.5 ml) solution for injection in cartridge; Omnitrope (10 mg/1.5 ml) solution for injection in cartridge; Omnitrope (15 mg/1.5 ml) solution for injection in cartridge\",",
    "Active Substance(s)": "Somatropin (recombinant human growth hormone) for all products\",",
    "Strength": "Omnitrope 1.3 mg/ml: 1.3 mg somatropin (4 IU) per ml\\nOmnitrope 5 mg/ml: 5 mg somatropin (15 IU) per ml\\nOmnitrope 5 mg/1.5 ml: 5 mg (15 IU) per 1.5 ml\\nOmnitrope 10 mg/1.5 ml: 10 mg (30 IU) per 1.5 ml\\nOmnitrope 15 mg/1.5 ml: 15 mg (45 IU) per 1.5 ml\",",
    "Pharmaceutical Form": "Omnitrope 1.3 mg/ml: Powder and solvent for solution for injection\\nOmnitrope 1.3 mg/ml: White powder and colourless solvent\\nOmnitrope 5 mg/ml: Powder and solvent for solution for injection\\nOmnitrope 5 mg/ml: White powder and colourless solution\\nOmnitrope 5 mg/1.5 ml: Solution for injection\\nOmnitrope 10 mg/1.5 ml: Solution for injection\\nOmnitrope 15 mg/1.5 ml: Solution for injection\",",
    "Route of Administration": "Omnitrope: Subcutaneous administration for all formulations\",",
    "Indications": "Growth hormone deficiency (GHD) in infants/children/adults\\nTurner syndrome\\nChronic renal insufficiency\\nShort children/adolescents born small for gestational age (SGA)\\nPrader-Willi syndrome (PWS)\",",
    "Posology": "1.3 mg/ml: 0.025\u20130.035 mg/kg/day or 0.7\u20131.0 mg/m\u00b2/day for GHD\\n0.035 mg/kg/day or 1.0 mg/m\u00b2/day appropted range for PWS\\n5 mg/ml: Same dosing as 1.3 mg/ml\\nInjectable solutions: Dosing based on body weight/kg or BSA/m\u00b2. For children, doses vary between 0.025\u20130.050 mg/kg depending on condition (GHD, Turner, CRI), up to 0.050 mg/kg or 1.4 mg/m\u00b2 for some indications\",",
    "Contraindications": "Hypersensitivity to somatropin or excipients\\nActive tumors (tumors must be inactive prior to use)\\nGrowth promotion in children with closed epiphyses\\nAcute critical illness (post-operative complications or trauma etc)\",",
    "Special Warnings and Precautions": "Traceability, Hypoadrenalism risk, Interaction with glucocorticoids\\nUse with oral oestrogen therapy: Possible dose adjustment needed\\nInsulin sensitivity: Monitor glucose levels\\nThyroid function: Monitor TSH and TFTs\\nNeoplasms: Monitor for tumor recurrence/second malignancies\\nSlipped capital femoral epiphysis monitoring\\nBenign intracranial hypertension monitoring\\nLeukaemia monitoring\\nPancreatitis monitoring\\nScoliosis monitoring\\nAcute critical illness: WARNING\\nElderly: start with lower doses\\nPWS: calorie restricted diet, sleep apnoea screening, respiratory infection monitoring, effective weight control before and during treatment\\nBenign intracranial hypertension: warning, provide instructions for fontoscopy\\n$\"Use only clear solution\", \"Mix only with provided equipment\",",
    "Marketing Authorisation Holder": "Sandoz GmbH (Address: Biochemiestr. 10, A-6250 Kundl, Austria)\\nNovartis Pharmaceutical Manufacturing GmbH (Address: Biochemiestr. 10, A-6336 Langkampfen, Austria)\",",
    "Marketing Authorisation Number": "EU/1/12/806/001, EU/1/12/806/002, EU/1/12/806/003, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008, EU/1/12/806/009",
    "Date of First Authorisation": "12 April 2006\",",
    "Date of Latest Renewal": "28 February 2011\",",
    "Shelf Life": "Omnitrope 1.3 mg/ml powder and solvent, unopened vials: 2 years\\nOmnitrope powder: 2 years\\nOmnitrope 5 mg/ml: Shelf life varies (mentioned as EU/1/06/332/001 and others without specific on 1.3 mg/ml revisits\\nOmnitrope powder and solvent: Shelf life mentioned as 3 years for 5 mg/ml\",",
    "Storage Conditions": "Refrigerated (2\u00b0C\u20138\u00b0C)\\nStore protected from light\\nDo not freeze\\nFrom reconstituted solution: Use within 2-28 days (depending on formulation\\nStore opened cartridge in refrigerator\",",
    "Package Description": "Omnitrope 1.3 mg/ml: 1 vial powder + 1 vial solvent. Outer carton. Single use\\nOmnitrope 5 mg/ml: Shelf life mentioned as EU/1/06/332/001 and others without specific storage conditions mentioned in the storage section\\nSolvent vial for Omnitrope 5 mg/ml is empty\\nOmnitrope 5 mg/1.5 ml: Pen with cartridge and SurePal 5\\nOmnitrope 10 mg/1.5 ml: Pen with cartridge and SurePal 10\\nOmnitrope 15 mg/1.5 ml: Pen with cartridge and SurePal 15\\n ' carries 1.5 ml, solution clear.\",",
    "Legal Category": "Marketing Authorisation Number, subject to medical prescription. Likely Category 2 (Prescription Only)\",",
    "ATC Code": "H01AC01 (Anterior pituitary lobe hormones and analogues)\",",
    "Manufacturers": "Novartis Pharmaceutical Manufacturing GmbH (A-6336 Langkampfen) mentioned separately in section A of Annex II.\\nThe cartridge stoppers and seals contained commercial designations.\",",
    "Excipients": "Powder: glycine, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate dihydrate/glycine, mannitol\" \"( for each formulation\\nSolvent: water or/Omnitrope 1.3 mg/ml complete list: glycine, disodium hydrogen phosphate heptahydrate, and dihydrate, see section 6.1",
    "File Name": "omnitrope-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "praluent-epar-product-information_en.pdf.pdf": {
    "Document Type": "Summary of Product Characteristics (SmPC)",
    "Product Name": "Praluent",
    "Active Substance(s)": "alirocumab",
    "Strength": "Each pre-filled pen or syringe contains: 75 mg alirocumab in 1 ml solution; 150 mg alirocumab in 1 ml solution; 300 mg alirocumab in 2 ml solution",
    "Pharmaceutical Form": "Solution for injection",
    "Route of Administration": "Subcutaneous use",
    "Indications": "Primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia; Established atherosclerotic cardiovascular disease (including in adolescents 12 years and older, and adults) as an adjunct to diet or background lipid-lowering therapy. Also indicated in children and adolescents 8 years and older with heterozygous familial hypercholesterolaemia (HeFH) alone or in combination with other lipid-lowering therapies.",
    "Posology": "Adults: Usual starting dose is 75 mg administered subcutaneously once every 2 weeks. Dose may be adjusted based on patient response or clinical need to 150 mg every 2 weeks or 300 mg once every 4 weeks. Paediatric patients (8 years and older): Dose depends on body weight (50 kg or less: 150 mg every 4 weeks; 50 kg or more: 300 mg every 4 weeks). Missed doses should be administered as soon as possible, then resume the original schedule.",
    "Contraindications": "Hypersensitivity to alirocumab or any of the excipients (histidine, sucrose, polysorbate 20, water for injections/fur water).",
    "Special Warnings and Precautions": "Traceability: Record the batch number. Allergic Reactions: May include general allergic reactions, hypersensitivity, angioedema, urticaria, eczema, and vasculitis. Renal Impairment: Use with caution in severe renal impairment. Hepatic Impairment: Use with caution in severe hepatic impairment. Interaction with other medicinal products: Alirocumab exposure may be reduced by concomitant statins, ezetimibe, or fenofibrate by approximately 35-40%. Pregnancy/Lactation: Not recommended during pregnancy or breastfeeding. Fertility: No effects on surrogate markers, but data limited.",
    "Marketing Authorisation Holder": "Sanofi Winthrop Industrie",
    "Marketing Authorisation Number": "EU/1/15/1031/001; EU/1/15/1031/002; EU/1/15/1031/003; EU/1/15/1031/004; EU/1/15/1031/005; EU/1/15/1031/006; EU/1/15/1031/007; EU/1/15/1031/008; EU/1/15/1031/009; EU/1/15/1031/010; EU/1/15/1031/011; EU/1/15/1031/012; EU/1/15/1031/013; EU/1/15/1031/014; EU/1/15/1031/015; EU/1/15/1031/016; EU/1/15/1031/017; EU/1/15/1031/018; EU/1/15/1031/019; EU/1/15/1031/020; EU/1/15/1031/021; EU/1/15/1031/022; EU/1/15/1031/023; EU/1/15/1031/024",
    "Date of First Authorisation": "23 September 2015",
    "Date of Latest Renewal": "2 June 2020",
    "Shelf Life": "3 years for Praluent 75 mg and 150 mg (pen or syringe formulations); 2 years for Praluent 300 mg pen",
    "Storage Conditions": "Store in a refrigerator (2\u00b0C to 8\u00b0C). Do not freeze. Protect from light by keeping in the outer carton. Can be stored outside the refrigerator (below 25\u00b0C), protected from light, for a single period not exceeding 30 days after removal from the refrigerator. Discard after 30 days. Protect the pen or syringe from light. Remove cap after opening and use immediately or discard.",
    "Package Description": "Pens: Blue cap and green/dark grey/activated button; Syringes: Green or grey polypropylene plunger rod. Pack sizes range from 1 to 6 items, individual pens, or multipacks.",
    "Legal Category": "A biologic/monoclonal antibody likely subject to prescription-only regulations as per standard EU authorization.",
    "ATC Code": "C10AX14",
    "Manufacturers": "Regeneron Pharmaceuticals, Regeneron Ireland DAC, Sanofi Winthrop Industrie; Sanofi Winthrop Industrie, Sanofi-Aventis Deutschland GmbH/Genzyme Ireland DAC for batch release",
    "Excipients": "histidine, sucrose, polysorbate 20, water for injections",
    "File Name": "praluent-epar-product-information_en.pdf.pdf",
    "Template ID": "1758026352056"
  },
  "prasugrel-viatris-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics (SPC/SmPC)",
    "Product Name": "Prasugrel Viatris 5 mg film-coated tablets; Prasugrel Viatris 10 mg film-coated tablets",
    "Active Substance(s)": "prasugrel",
    "Strength": "5 mg tablet (equivalent to 5 mg prasugrel) or 10 mg tablet (equivalent to 10 mg prasugrel). Special strengths: 5 mg maintenance dose for patients \u226575 years or <60 kg",
    "Pharmaceutical Form": "Film-coated tablets for oral use. Prasugrel Viatris 5 mg tablets are yellow, capsule-shaped, biconvex. Prasugrel Viatris 10 mg tablets are beige, capsule-shaped, biconvex",
    "Route of Administration": "Oral",
    "Indications": "Prevention of atherothrombotic events (myocardial infarction, stroke, death) in adult patients with acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing primary or delayed PCI, usually coadministered with acetylsalicylic acid (ASA)",
    "Posology": "Adults: 60 mg loading dose followed by 10 mg daily for general population. Exceptions: \u226575 years -> reduced maintenance dose of 5 mg; <60 kg -> reduced maintenance dose of 5 mg; Renal/hepatic impairment -> no dose adjustment needed but caution advised. Paediatric population: not indicated (<18 years, except specified study)",
    "Contraindications": "Hypersensitivity to active substance or excipients, active pathological bleeding, history of stroke or TIA, severe hepatic impairment (Child Pugh Class C)",
    "Special Warnings and Precautions": "Risk of bleeding (gastrointestinal tract predominant); caution in patients \u226575 years, <60 kg, renal/hepatic impairment; reduce dose in specified cases; surgical patients may need temporary discontinuation \u22657 days before procedure; hypersensitivity reactions including angioedema; risk of bleeding if loading dose administered too early in NSTEMI (average 4+ hours before PCI increases bleeding risk); interaction with warfarin, NSAIDs, morphine, CYP3A inhibitors/inducers may be clinically significant",
    "Marketing Authorisation Holder": "Viatris Limited",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "16 May 2018",
    "Date of Latest Renewal": "20 March 2023",
    "Shelf Life": "2 years",
    "Storage Conditions": "5 mg formulations: Do not store above 30\u00b0C. Protect from moisture (original package). 10 mg formulations (bottles): Do not store above 25\u00b0C, protect from moisture. Blister packs: Do not store above 30\u00b0C, protect from moisture. All formulations should be protected from light if specified by the particular packaging.",
    "Package Description": "Available in plastic bottles containing desiccant and 28/30 tablets, and/or foil-sealed blisters containing various combinations of 28, 30, 84, 90, 98 tablets, with specific combinations for 5mg and 10mg forms. Cartons contain 1 bottle or blister pack.",
    "Legal Category": "Not explicitly stated, but likely Prescription Only Medication (POM) given the nature of the product and context",
    "ATC Code": "B01AC22",
    "Manufacturers": "Gerard Laboratories / Mylan Dublin, Ireland; Mylan Hungary Kft., Hungary; McDermott Laboratories / Mylan, Ireland",
    "Excipients": "Common excipients: microcrystalline cellulose, mannitol, crospovidone, silica colloidal anhydrous, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), glyceryl monocaprylocaprate, sodium lauryl sulfate. For 5mg only: iron oxide yellow (E172); for 10mg additionally: iron  oxide red (E172), sunset yellow FCF aluminium lake (E110)",
    "File Name": "prasugrel-viatris-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "ryzodeg-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen; Ryzodeg 100 units/mL FlexPen solution for injection in pre-filled pen; Ryzodeg 100 units/mL Penfill solution for injection in cartridge",
    "Active Substance(s)": "insulin degludec / insulin aspart* in a ratio of 70/30 (equivalent to 2.56 mg insulin degludec and 1.05 mg insulin aspart).",
    "Strength": "100 units/mL, with one pre-filled pen/cartridge containing 300 units of insulin degludec/insulin aspart",
    "Pharmaceutical Form": "Solution for injection, pre-filled pen or cartridge",
    "Route of Administration": "Subcutaneous use only",
    "Indications": "Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years",
    "Posology": "Dosed individually based on patient needs; Use with main meal(s); Regular blood glucose monitoring; Dose adjustments based on fasting plasma glucose; Adjustments for increased physical activity, diet change, or concomitant illness; Special considerations for elderly, renal/hepatic impairment, and pediatric populations (especially 2-5 years old)",
    "Contraindications": "Hypersensitivity to the active substances or any of the excipients listed in section 6.1",
    "Special Warnings and Precautions": "Avoid intravenous or intramuscular administration; Risk of hypoglycaemia (especially in children 2-5 years, switch from other basal/premix insulin without adjustment, frequent/absent awareness of hypoglycaemia); Can cause hyperglycaemia; Use only clear, colourless solution; No reuse of needles; Hypersensitivity reactions; Lipodystrophy/cutaneous amyloidosis at injection sites; Avoid mixing with other medicinal products; Proper disposal of waste; Use only for single patient; Not recommended during breastfeeding under certain conditions",
    "Marketing Authorisation Holder": "Novo Nordisk A/S; Novo Nordisk Production SAS",
    "Marketing Authorisation Number": "EU/1/12/806/001, EU/1/12/806/002, EU/1/12/806/003, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008, EU/1/12/806/009",
    "Date of First Authorisation": "21 January 2013",
    "Date of Latest Renewal": "21 September 2017",
    "Shelf Life": "30 months (non-refrigerated after first opening, up to maximum 4 weeks; properly stored)",
    "Storage Conditions": "Before first use: Refrigerate at 2\u00b0C\u20138\u00b0C; Do not freeze; Protect from light. After first opening (if carried as spare): 2\u00b0C\u20138\u00b0C or not above 30\u00b0C, depending on formulation or refrigerate, protect from light; Do not refrigerate for specific formulations; Store in outer carton to protect from light",
    "Package Description": "Ryzodeg 100 units/mL FlexTouch/FlexPen: 3 mL solution in cartridge made of type 1 glass, halobutyl plunger; Pens made of polypropylene; FlexTouch: Pack sizes 1 pen (with/without needles), 5 pens; FlexPen: 5 pens; Ryzodeg Penfill: 3 mL solution in cartridge made of type 1 glass, halobutyl plunger; Pack sizes 5 or 10 cartridges; Disposable with Novo Nordisk insulin delivery systems/syringes/n needles",
    "Legal Category": "Prescription only",
    "ATC Code": "A10AD06",
    "Manufacturers": "Novo Nordisk A/S (DK), Novo Nordisk Production SAS (FR)",
    "Excipients": "Glycerol, metacresol, phenol, sodium chloride, zinc acetate, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injections",
    "File Name": "ryzodeg-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "sitagliptin-metformin-hydrochloride-mylan-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics, SmPC, Product Information",
    "Product Name": "Sitagliptin/Metformin hydrochloride Mylan",
    "Active Substance(s)": "sitagliptin hydrochloride monohydrate and metformin hydrochloride",
    "Strength": "50 mg/850 mg and 50 mg/1000 mg",
    "Pharmaceutical Form": "Film-coated tablet",
    "Route of Administration": "Oral use",
    "Indications": "Treatment of type 2 diabetes mellitus",
    "Posology": "Take one tablet twice daily with meals",
    "Contraindications": "Hypersensitivity to the active substances or to any of the excipients, severely reduced kidney function, uncontrolled diabetes, etc.",
    "Special Warnings and Precautions": "Risk of lactic acidosis, pancreatitis, hypersensitivity reactions, etc.",
    "Marketing Authorisation Holder": "Mylan Pharmaceuticals Limited",
    "Marketing Authorisation Number": "EU/1/21/1619/001, EU/1/21/1619/002, etc.",
    "Date of First Authorisation": "16 February 2022",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "2 years",
    "Storage Conditions": "Store out of the sight and reach of children",
    "Package Description": "Film-coated tablet, blister packs containing 14, 56, 98, or 196 film-coated tablets, etc.",
    "Legal Category": "Prescription only",
    "ATC Code": "A10BD07",
    "Manufacturers": "Mylan Pharmaceuticals Limited, Medis International as, Mylan Hungary Kft, etc.",
    "Excipients": "microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, etc.",
    "File Name": "sitagliptin-metformin-hydrochloride-mylan-epar-product-information_en.pdf",
    "Template ID": "1758024870709"
  },
  "wegovy-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Wegovy",
    "Active Substance(s)": "semaglutide",
    "Strength": "0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg",
    "Pharmaceutical Form": "Solution for injection",
    "Route of Administration": "Subcutaneous use",
    "Indications": "Weight loss and weight management in adults with obesity (BMI \u226530 kg/m\u00b2) or overweight (BMI \u226527 kg/m\u00b2 to <30 kg/m\u00b2) with weight-related health problems, and in adolescents ages 12 years and above with obesity and body weight >60 kg",
    "Posology": "The recommended dose is 2.4 mg once weekly, starting at 0.25 mg and escalating over 16 weeks",
    "Contraindications": "Hypersensitivity to semaglutide or other ingredients, type 1 diabetes, severely reduced kidney function, severely reduced liver function, severe heart failure, diabetic eye disease (retinopathy)",
    "Special Warnings and Precautions": "Dehydration, inflammation of the pancreas (acute pancreatitis), low blood sugar (hypoglycaemia) in patients with type 2 diabetes, diabetic eye disease (retinopathy)",
    "Marketing Authorisation Holder": "Novo Nordisk A/S",
    "Marketing Authorisation Number": "EU/1/21/1608/001, EU/1/21/1608/002, EU/1/21/1608/003, EU/1/21/1608/004, EU/1/21/1608/005, EU/1/21/1608/006, EU/1/21/1608/007, EU/1/21/1608/008, EU/1/21/1608/009, EU/1/21/1608/010, EU/1/21/1608/011, EU/1/21/1608/012",
    "Date of First Authorisation": "06 January 2022",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "1 year for single-dose pre-filled pens, 2 years for FlexTouch pens before use, 6 weeks after first use",
    "Storage Conditions": "Store in a refrigerator (2\u00b0C \u2013 8\u00b0C), do not freeze, keep away from the cooling element",
    "Package Description": "Pre-filled pens, single-dose or multi-dose, with needles",
    "Legal Category": "Prescription only",
    "ATC Code": "A10BJ06",
    "Manufacturers": "Novo Nordisk A/S, Novo Nordisk Production SAS",
    "Excipients": "Disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections",
    "File Name": "wegovy-epar-product-information_en.pdf",
    "Template ID": "1758024870709"
  },
  "winrevair-epar-product-information_en.pdf.pdf": {
    "Document Type": "Product Information",
    "Product Name": "Winrevair",
    "Active Substance(s)": "sotatercept",
    "Strength": "45 mg and 60 mg",
    "Pharmaceutical Form": "powder and solvent for solution for injection",
    "Route of Administration": "subcutaneous injection",
    "Indications": "pulmonary arterial hypertension (PAH) in adults",
    "Posology": "one injection every 3 weeks, starting dose 0.3 mg/kg, target dose 0.7 mg/kg",
    "Contraindications": "hypersensitivity to sotatercept or any of the other ingredients, platelet counts consistently < 50 x 10^9/L",
    "Special Warnings and Precautions": "increased risk of serious bleeding, erythrocytosis, severe thrombocytopenia",
    "Marketing Authorisation Holder": "Merck Sharp & Dohme B.V.",
    "Marketing Authorisation Number": "EU/1/24/1850/001, EU/1/24/1850/002, EU/1/24/1850/003, EU/1/24/1850/004",
    "Date of First Authorisation": "22 August 2024",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "3 years, after reconstitution 4 hours at 30\u00b0C",
    "Storage Conditions": "refrigerate at 2-8\u00b0C, protect from light",
    "Package Description": "2 mL glass vial, 1 prefilled syringe, 1 vial adapter, 1 dosing syringe, 1 needle, 4 alcohol wipes",
    "Legal Category": "\"Legal Category\": \"Not found\",",
    "ATC Code": "\"ATC Code\": \"Not found\",",
    "Manufacturers": "Abbvie Bioresearch Center, Merc k Sharp & Dohme B.V.",
    "Excipients": "citic acid monohydrate, sodium citrate, polysorbate 80, sucrose, water for injections",
    "File Name": "winrevair-epar-product-information_en.pdf.pdf",
    "Template ID": "1758024870709"
  },
  "saxenda-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Saxenda",
    "Active Substance(s)": "Liraglutide",
    "Strength": "6 mg/ml",
    "Pharmaceutical Form": "Solution for injection",
    "Route of Administration": "Subcutaneous use only",
    "Indications": "Weight management in adults, adolescents and children for Prader-Willi Syndrome with obesity (based on etiology and weight \u226560 kg)",
    "Posology": "Adults: starting at 0.6 mg once daily, escalated in 0.6 mg increments weekly to 3.0 mg daily. Adolescents: similar to adults.",
    "Contraindications": "Hypersensitivity to liraglutide or any excipient, severe renal impairment, severe hepatic impairment, heart failure NYHA class IV",
    "Special Warnings and Precautions": "Aspiration during anesthesia, aspiration risk, use subcutaneously, risk of pancreatitis, cholelithiasis, hypoglycemia risk in diabetics, endocrine tumor, use in pregnancy/breastfeeding, fluid loss/dehydration, thyroid disorders, heart rate increase, late-onset dumping syndrome, dysphagia, allergic reactions, injection site amyloidosis.",
    "Marketing Authorisation Holder": "Novo Nordisk A/S",
    "Marketing Authorisation Number": "EU/1/15/992/001-003",
    "Date of First Authorisation": "23 March 2015",
    "Date of Latest Renewal": "09 December 2019",
    "Shelf Life": "Original packaging: 30 months. After first use: 1 month",
    "Storage Conditions": "Store below 8\u00b0C in refrigerator (2-8\u00b0C). Do not freeze. After first use: store below 30\u00b0C or in refrigerator. Protect from light. Keep container cap on after use.",
    "Package Description": "Single or multidose patient pen (pre-filled multidose pen, 3 ml containing doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg).",
    "Legal Category": "Prescription only medication",
    "ATC Code": "A10BA02",
    "Manufacturers": "Liraglutide: Novo Nordisk A/S (Denmark). Packaging: Pens made from glass, polypropylene, polyacetal, polycarbonate, acrylonitrile butadiene styrene.",
    "Excipients": "Disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide, water for injections",
    "File Name": "saxenda-epar-product-information_en.pdf",
    "Template ID": "1758026352056"
  },
  "talmanco-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Talmanco",
    "Active Substance(s)": "tadalafil",
    "Strength": "20 mg",
    "Pharmaceutical Form": "film-coated tablets",
    "Route of Administration": "oral use",
    "Indications": "pulmonary arterial hypertension in adults and in children aged 2 years and above",
    "Posology": "The usual dose is two 20 mg tablets taken once a day. For children weighing less than 40 kg, the recommended dose is one 20 mg tablet taken once a day.",
    "Contraindications": "Hypersensitivity to the active substance or to any of the excipients, acute myocardial infarction within the last 90 days, severe hypotension, use with nitrates, use with riociguat",
    "Special Warnings and Precautions": "Cardiovascular diseases, vision, decreased or sudden hearing loss, renal and hepatic impairment, priapism and anatomical deformation of the penis",
    "Marketing Authorisation Holder": "Viatris Limited",
    "Marketing Authorisation Number": "EU/1/16/1153/001, EU/1/16/1153/002, EU/1/16/1153/003, EU/1/16/1153/004",
    "Date of First Authorisation": "09 January 2017",
    "Date of Latest Renewal": "09 November 2021",
    "Shelf Life": "3 years",
    "Storage Conditions": "This medicinal product does not require any special storage conditions",
    "Package Description": "white, film-coated, round, biconvex, bevelled edge tablet marked with \u2018M\u2019 on one side of the tablet and \u2018TA20\u2019 on the other side",
    "Legal Category": "prescription only",
    "ATC Code": "G04BE08",
    "Manufacturers": "McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin, Mylan Hungary Kft, Mylan Germany GmbH",
    "Excipients": "lactose, povidone, sodium laurilsulfate, poloxamer 188, anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, lactose monohydrate, hypromellose, titanium dioxide, triacetin",
    "File Name": "talmanco-epar-product-information_en.pdf",
    "Template ID": "1758021973065"
  },
  "vildagliptin-metformin-hydrochloride-accord-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics, SmPC, Product Information",
    "Product Name": "Vildagliptin/Metformin hydrochloride Accord",
    "Active Substance(s)": "Vildagliptin and Metformin hydrochloride",
    "Strength": "50 mg/850 mg and 50 mg/1000 mg",
    "Pharmaceutical Form": "Film-coated tablets",
    "Route of Administration": "Oral use",
    "Indications": "Type 2 diabetes mellitus",
    "Posology": "One film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken twice a day",
    "Contraindications": "Hypersensitivity to the active substance or to any of the excipients, Any type of acute metabolic acidosis, Diabetic pre-coma, Severe renal failure, Acute conditions with the potential to alter renal function, Acute or chronic disease which may cause tissue hypoxia, Hepatic impairment, Acute alcohol intoxication, alcoholism, Breast-feeding",
    "Special Warnings and Precautions": "Lactic acidosis, Angioedema, Hepatitis, Pancreatitis, Skin disorders, Acute pancreatitis, Hypoglycaemia, Surgery, Interaction with other medicinal products and other forms of interaction",
    "Marketing Authorisation Holder": "Accord Healthcare S.L.U",
    "Marketing Authorisation Number": "EU/1/21/1611/001 -006",
    "Date of First Authorisation": "24 March 2022",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "2 years",
    "Storage Conditions": "This medicinal product does not require any special storage conditions",
    "Package Description": "Film-coated tablets, Aluminium/Aluminium blister, Pack sizes of 30, 60 or 180 film-coated tablets",
    "Legal Category": "Prescription only",
    "ATC Code": "A10BD08",
    "Manufacturers": "LABORATORI FUNDACI\u00d3 DAU, Pharmadox Healthcare Ltd, Accord Healthcare Polska Sp. z o.o, Accord Healthcare B.V",
    "Excipients": "Hydroxypropylcellulose, low-substitute hydroxypropylcellulose, microcrystalline cellulose, magnesium stearate, Hypromellose, titanium dioxide (E171), iron oxide yellow (E172), macrogol, talc",
    "File Name": "vildagliptin-metformin-hydrochloride-accord-epar-product-information_en.pdf",
    "Template ID": "1758021973065"
  },
  "trepulmix-epar-product-information_en.pdf": {
    "Document Type": "Summary of Product Characteristics, SmPC, Product Information",
    "Product Name": "Trepulmix",
    "Active Substance(s)": "Treprostinil",
    "Strength": "1 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml",
    "Pharmaceutical Form": "Solution for infusion",
    "Route of Administration": "Subcutaneous use",
    "Indications": "Treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment",
    "Posology": "The recommended initial infusion rate is 1.25 ng/kg/min. If this initial dose is poorly tolerated, the infusion rate should be reduced to 0.625 ng/kg/min. The dose should be adjusted on an individual basis and under medical supervision",
    "Contraindications": "Hypersensitivity to the active substance or to any of the excipients, Pulmonary veno-occlusive disease, Severe decompensated left heart failure, Severe hepatic impairment (Child-Pugh Class C), Active gastrointestinal ulcer, intracranial haemorrhage, gastrointestinal injury or other gastrointestinal bleeding",
    "Special Warnings and Precautions": "The decision to initiate therapy with treprostinil should take into consideration the high probability that continuous infusion will have to be continued for a prolonged period. Treprostinil is a potent pulmonary and systemic vasodilator. In subjects presenting with low systemic arterial pressure, treprostinil treatment may increase the risk of systemic hypotension",
    "Marketing Authorisation Holder": "SciPharm S\u00e0rl",
    "Marketing Authorisation Number": "EU/1/19/1419/001, EU/1/19/1419/002, EU/1/19/1419/003, EU/1/19/1419/004",
    "Date of First Authorisation": "03 April 2020",
    "Date of Latest Renewal": "13 December 2024",
    "Shelf Life": "3 years (unopened vial), 30 days (after first opening)",
    "Storage Conditions": "This medicinal product does not require any special storage conditions. For storage conditions after first opening of the medicinal product, see section 6.3",
    "Package Description": "10 ml clear glass vial sealed with a rubber stopper and a colour-coded cap",
    "Legal Category": "Prescription only",
    "ATC Code": "B01AC21",
    "Manufacturers": "AOP Orphan Pharmaceuticals GmbH",
    "Excipients": "Sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid, metacresol, and water for injections",
    "File Name": "trepulmix-epar-product-information_en.pdf",
    "Template ID": "1758021973065"
  },
  "application_test1": {
    "Document Type": "Summary of Product Characteristics, SmPC, Product Information",
    "Product Name": "Awiqli",
    "Active Substance(s)": "insulin icodec",
    "Strength": "700 units/mL",
    "Pharmaceutical Form": "Solution for injection in pre-filled pen",
    "Route of Administration": "Subcutaneous use",
    "Indications": "Treatment of diabetes mellitus in adults",
    "Posology": "Once-weekly subcutaneous administration, dose can be adjusted based on fasting plasma glucose",
    "Contraindications": "Hypersensitivity to the active substance or to any of the excipients",
    "Special Warnings and Precautions": "Risk of hypoglycaemia, special warnings for patients with type 1 diabetes, patients with renal or hepatic impairment",
    "Marketing Authorisation Holder": "Novo Nordisk A/S",
    "Marketing Authorisation Number": "EU/1/24/1815/001, EU/1/24/1815/002, EU/1/24/1815/003, EU/1/24/1815/004, EU/1/24/1815/005, EU/1/24/1815/006, EU/1/24/1815/007, EU/1/24/1815/008, EU/1/24/1815/009, EU/1/24/1815/010, EU/1/24/1815/011, EU/1/24/1815/012, EU/1/24/1815/013, EU/1/24/1815/014",
    "Date of First Authorisation": "17 May 2024",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "3 years",
    "Storage Conditions": "Store in a refrigerator (2 \u00b0C - 8 \u00b0C), do not freeze, keep the cap on the pen to protect from light",
    "Package Description": "Pre-filled pen containing 700 units of insulin icodec in 1 mL solution, 1.5 mL solution, or 3 mL solution",
    "Legal Category": "Prescription only",
    "ATC Code": "A10AE07",
    "Manufacturers": "Novo Nordisk A/S",
    "Excipients": "Glycerol, metacresol, phenol, zinc acetate, sodium chloride, hydrochloric acid, sodium hydroxide, water for injections",
    "File Name": "application_test1",
    "Template ID": "1758023541274"
  }
}